Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication
Fig 3
Plasma concentration of IL-1β, IL-1ra, IL-6 and IL-8 before (open circles; week 13) and after (filled circles; week 25) antagonist administration in ART-untreated and ART-treated SIV infected macaques.